If your antidepressant isn’t working, you’re not an outlier. The largest real-world study of antidepressant treatment found that only about 25% of patients achieved remission on their first medication. That number drops with each subsequent attempt: 21% on a second try, 13% on a third, and just 10% on a fourth. So the experience of trying a medication and feeling no better is, statistically, the most common outcome at each step. The reasons range from genetics and misdiagnosis to hidden medical conditions and inflammation, and understanding which applies to you can change the entire direction of your treatment.
Your Body May Process the Drug Too Fast or Too Slow
Your liver breaks down antidepressants using a family of enzymes, and the genes controlling those enzymes vary dramatically from person to person. Two enzymes in particular matter most for common antidepressants. Depending on your genetic makeup, you fall somewhere on a spectrum from “poor metabolizer” to “ultrarapid metabolizer.”
If you’re an ultrarapid metabolizer, your body clears the drug before it can reach effective levels in your brain. You take the full prescribed dose, but your bloodstream never sees enough of it to make a difference. On the other end, poor metabolizers break the drug down so slowly that it builds up, causing side effects severe enough to force you off the medication before it has a chance to help. Either way, the standard dose doesn’t fit your biology.
Pharmacogenomic testing, sometimes called a “gene test for medications,” can identify which category you fall into. It won’t tell you exactly which antidepressant will work, but it can rule out drugs your body can’t process properly. If you’ve failed multiple medications, this testing is worth discussing with your prescriber.
You May Not Have the Condition Being Treated
Bipolar II disorder is one of the most commonly missed diagnoses in people labeled with standard depression. The depressive episodes in bipolar II look identical to major depression on paper. The diagnostic criteria are the same. The critical difference is that people with bipolar II also experience hypomanic episodes: stretches of elevated energy, reduced need for sleep, and increased productivity that feel good and rarely prompt someone to seek help. Because patients almost never report these episodes, clinicians see only the depression and prescribe accordingly.
Antidepressants don’t reliably treat bipolar depression. For some patients they simply don’t work; for others they can worsen the overall course of the illness. About 12% of people with bipolar II experience a switch into hypomania when put on an antidepressant. If you’ve ever had a period of days where you felt unusually energized, needed little sleep, took on ambitious projects, or spent money impulsively, and then later crashed into depression, bring that history to your provider. It could reframe your entire treatment plan.
A Medical Condition May Be Driving Your Symptoms
Several common, treatable health problems produce symptoms that overlap almost perfectly with depression: fatigue, low motivation, difficulty concentrating, weight changes, and a flat or hopeless mood. No antidepressant will fix these symptoms if the underlying cause is physical.
Hypothyroidism is a well-established culprit. An underactive thyroid slows everything down, including brain function, and produces depression-like cognitive dysfunction, apathy, and psychomotor slowing. Some researchers have proposed a “brain hypothyroidism” theory of depression, where thyroid hormone levels in the brain drop even when blood tests look normal, due to problems with how the hormone crosses the blood-brain barrier.
Vitamin D deficiency is another common factor. More than 50% of psychiatric inpatients in the United States have vitamin D levels below 10 ng/ml, which is severely deficient. Low vitamin D has been linked to both depressive symptoms and thyroid dysfunction, meaning the two problems often compound each other.
Obstructive sleep apnea is a less obvious but important consideration, especially if your depression has resisted multiple treatments. Sleep apnea fragments your sleep and reduces oxygen delivery to your brain throughout the night. Research into treatment-resistant depression has specifically investigated whether undiagnosed sleep apnea is a hidden driver, because the resulting daytime sleepiness, cognitive fog, and low energy look exactly like depression that won’t respond to medication. If you snore, wake up tired despite adequate hours in bed, or have been told you stop breathing at night, a sleep study could reveal a treatable cause of your symptoms.
Inflammation Can Block How SSRIs Work
Most common antidepressants work by increasing serotonin availability in the brain. But chronic inflammation in the body can undermine that mechanism at a biological level. Inflammatory molecules reduce serotonin availability through two routes: they ramp up the proteins that pull serotonin out of the spaces between brain cells, and they divert tryptophan (the raw material your brain uses to make serotonin) away from serotonin production.
A study published in The British Journal of Psychiatry found that people with treatment-resistant depression had significantly higher levels of C-reactive protein, a blood marker of inflammation, compared to both treatment-responsive patients and healthy controls. The difference wasn’t subtle. This suggests that for a subset of people, the standard serotonin-based approach fails not because of the drug itself, but because inflammation is actively working against it.
What drives this inflammation varies: obesity, autoimmune conditions, chronic stress, poor diet, and sedentary lifestyle all contribute. Addressing inflammation through its root causes, or potentially through anti-inflammatory treatments, may open a pathway that antidepressants alone cannot.
The Dose or Duration May Be Wrong
Clinical guidelines and the FDA consider 6 to 8 weeks an adequate trial period for an antidepressant. That means if you’ve been on a medication for three or four weeks without improvement, it may genuinely be too early to call it a failure. The median trial duration in research studies is 8 weeks, though some extend to 12.
Equally important is dose. Many patients remain on a starting dose that was never titrated upward to a therapeutic level. An “adequate trial” in clinical terms means a sufficient dose maintained for a sufficient duration. If your prescriber started you low and never adjusted, or if you reduced your dose on your own because of early side effects, the medication may not have had a fair test.
What “Treatment-Resistant” Actually Means
If you’ve tried two or more antidepressants at adequate doses for adequate durations without meaningful improvement, your depression meets the most widely accepted definition of treatment-resistant depression. This isn’t a rare label. Given the remission rates from real-world data, a large portion of people treated for depression will eventually meet this threshold.
The designation matters because it opens the door to different treatment strategies. The two main approaches are augmentation (adding a second medication to your current antidepressant) and switching (moving to an entirely different type of drug).
Augmentation Options
Adding a low-dose atypical antipsychotic to an existing antidepressant is one of the most studied augmentation strategies. A large trial published in the New England Journal of Medicine tested this approach in adults over 60 and found that adding aripiprazole to an existing antidepressant was one of the more effective first-line augmentation options. Bupropion, a different class of antidepressant, can also be added on top of an SSRI. If those approaches fail, lithium augmentation is a well-established second-line option with decades of evidence behind it.
Newer Approaches
For people who haven’t responded to multiple medication strategies, two newer options target the brain differently than traditional antidepressants. Intranasal esketamine works on the glutamate system rather than serotonin, and in clinical trials it achieved response rates of about 70% and remission rates near 50% when combined with a new antidepressant. Repetitive transcranial magnetic stimulation (rTMS), which uses magnetic pulses to stimulate specific brain networks involved in mood regulation, showed response rates around 50% and remission rates of 30%. Both are typically reserved for people who have already failed standard treatments.
What to Do With All of This
If your antidepressant isn’t working, the single most useful step is to work backward through the possible explanations rather than simply trying the next pill on the list. Ask for basic bloodwork: thyroid function and vitamin D at minimum. Consider whether bipolar II could be in the picture by honestly reviewing your mood history, including the highs. If you have risk factors for sleep apnea, pursue testing. If you’ve been on multiple medications without relief, ask about pharmacogenomic testing to rule out a metabolism mismatch.
The pattern of trying one SSRI after another without investigating why the first ones failed is common, but it’s not the only path. Each failed trial carries information about what’s actually going on, and using that information strategically gives you a much better chance of finding something that works.